Demographics and Geographic Accessibility of Invasive Fungal Infection Clinical Trial Sites - Takeaways - MDSpire

Demographics and Geographic Accessibility of Invasive Fungal Infection Clinical Trial Sites

  • By

  • Lucy X. Li

  • Jiashu Xue

  • Olivia S. Kates

  • Robin K. Avery

  • Sean X. Zhang

  • John W. Baddley

  • Christine M. Durand

  • Nitipong Permpalung

  • June 11, 2026

  • 0 min

Share

  • 1

    Clinical trials for invasive fungal infections (IFIs) are unevenly distributed, with a concentration in urban areas and significant regional variation.

  • 2

    Socioeconomically disadvantaged and rural populations face barriers to accessing clinical trials, potentially leading to disparities in trial representation.

  • 3

    A majority of residents near trial sites are of working age, with racial minorities more represented in prophylaxis trial catchments compared to treatment sites.

  • 4

    Many residents in trial catchment areas lack vehicle access, which may hinder participation in clinical trials despite proximity to sites.

  • 5

    The study underscores the need for equitable trial access strategies to capture diverse epidemiological data and improve antifungal drug development.

Original Source(s)

Demographics and Geographic Accessibility of Invasive Fungal Infection Clinical Trial Sites

  • by Lucy X. Li, Jiashu Xue, Olivia S. Kates, Robin K. Avery, Sean X. Zhang, John W. Baddley, Christine M. Durand, Nitipong Permpalung

  • June 11, 2026

Related Content

Medical Oddities: The Economics of Shut-Eye

Sleep became a commodity, tea became a therapy, and cats got a reprieve this week.

Long-Acting Injectable Antiretroviral Therapy in Medicare-Enrolled Adults With HIV

Temporal and anatomic determinants of central-line–associated bloodstream infection risk in a tertiary PICU: a 3-year time-to-event and competing-risk analysis